Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.44 |
| ▸ | KDR | P35968 | 9/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882429 | 0.85 | PDGFRB (0.42) | PDGFRBKDRAAK1DGAT1GSK3A | |
| SCHEMBL18437068 | 0.84 | PDGFRB (0.41) | PDGFRBKDRAAK1ALPLDGAT1 | |
| SCHEMBL15882529 | 0.84 | PDGFRB (0.41) | PDGFRBKDRAAK1DGAT1CA1 | |
| SCHEMBL3515122 | 0.83 | CSF1R (0.39) | PDGFRBKDRAAK1ALPLDGAT1 | |
| SCHEMBL29555798 | 0.83 | ALPL (0.46) | PDGFRBKDRAAK1ALPLDGAT1 | |
| SCHEMBL407919 | 0.83 | ALPL (0.46) | PDGFRBKDRAAK1ALPLDGAT1 | |
| SCHEMBL67212 | 0.82 | AAK1 (0.43) | PDGFRBKDRAAK1 | |
| SCHEMBL15882535 | 0.82 | PDGFRB (0.41) | PDGFRBKDRAAK1DGAT1 | |
| SCHEMBL29599536 | 0.82 | AAK1 (0.43) | PDGFRBKDRAAK1 | |
| SCHEMBL29858100 | 0.82 | JAK2 (0.43) | PDGFRBKDRAAK1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-01-08 | — | — | US | claimed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | claimed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | claimed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022166920-A1 | PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-107406462-B | Tricyclic DLK inhibitors and uses thereof | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | PDGFRB 4361/4885KDR 4662/4885AAK1 3761/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | PDGFRB 2462/4885KDR 972/4885AAK1 161/4885 |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | PDGFRB 293/4885KDR 462/4885AAK1 719/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | PDGFRB 4361/4885KDR 4662/4885AAK1 3761/4885 |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | PDGFRB 2566/4885KDR 4756/4885AAK1 4644/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PDGFRB 2417/4885KDR 1094/4885AAK1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.